Yu Zhu

300 Guangzhou Road
Nanjing, 210029, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 97 publications

The IL-33-ILC2 axis: a key regulator of type 2 immunity in respiratory disease.

The IL-33-ILC2 axis: a key regulator of type 2 immunity in respiratory disease.

Journal: Frontiers in immunology

Published: May 26, 2026

Long-Term Results of Busulfan Plus High-Dose Idarubicin as a Conditioning Regimen to Autologous Stem Cell Transplantation Following Cytarabine Consolidation in Young Patients with Favorable or Intermediate-Risk Acute Myeloid Leukemia.

Long-Term Results of Busulfan Plus High-Dose Idarubicin as a Conditioning Regimen to Autologous Stem Cell Transplantation Following Cytarabine Consolidation in Young Patients with Favorable or Intermediate-Risk Acute Myeloid Leukemia.

Journal: Blood and lymphatic cancer : targets and therapy

Published: May 01, 2026

Renal Dysfunction in Patients with CML on Long-Term First-Line TKI Therapy: A Single-Center Analysis.

Renal Dysfunction in Patients with CML on Long-Term First-Line TKI Therapy: A Single-Center Analysis.

Journal: The oncologist

Published: April 01, 2026

Personalized in vitro models reveal functional impact of a KCNH2 mutation and enable drug screening in LQTS2.

Personalized in vitro models reveal functional impact of a KCNH2 mutation and enable drug screening in LQTS2.

Journal: Heart rhythm O2

Published: March 30, 2026

Interplay Between Psychological Burden, Economic Stress, and Quality of Life in Chronic Myeloid Leukemia Care: An Integrated Analysis.

Interplay Between Psychological Burden, Economic Stress, and Quality of Life in Chronic Myeloid Leukemia Care: An Integrated Analysis.

Journal: JCO oncology practice

Published: March 10, 2026

Off-target inhibition of PKA RII by crizotinib leads to reduced hERG expression and acquired QT prolongation.

Off-target inhibition of PKA RII by crizotinib leads to reduced hERG expression and acquired QT prolongation.

Journal: Heart rhythm

Published: February 24, 2026

Characteristics and Prognostic Implications in Newly Diagnosed KMT2Ar AML: A Multicenter Study of the ECLA Group.

Characteristics and Prognostic Implications in Newly Diagnosed KMT2Ar AML: A Multicenter Study of the ECLA Group.

Journal: American journal of hematology

Published: December 12, 2025

Association between venetoclax concentration and febrile neutropenia in acute leukemia: a retrospective analysis.

Association between venetoclax concentration and febrile neutropenia in acute leukemia: a retrospective analysis.

Journal: European journal of clinical pharmacology

Published: December 01, 2025

Real-World Evidence-Based Study on Treatment-Free Remission in Chronic Myeloid Leukemia.

Real-World Evidence-Based Study on Treatment-Free Remission in Chronic Myeloid Leukemia.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: November 05, 2025

Efficacy and safety of selinexor combined with VRD in newly diagnosed multiple myeloma with EMD: a phase 2 trial.

Efficacy and safety of selinexor combined with VRD in newly diagnosed multiple myeloma with EMD: a phase 2 trial.

Journal: Blood advances

Published: October 29, 2025

Imatinib and nilotinib are equally successful in achieving therapy-free remission.

Imatinib and nilotinib are equally successful in achieving therapy-free remission.

Journal: Blood cancer journal

Published: October 22, 2025

Efficacy and safety of 50 mg versus 100 mg daily frontline dasatinib therapy in chronic-phase chronic myeloid leukemia: a non-controlled, observational dose-comparative cohort study.

Efficacy and safety of 50 mg versus 100 mg daily frontline dasatinib therapy in chronic-phase chronic myeloid leukemia: a non-controlled, observational dose-comparative cohort study.

Journal: BMC cancer

Published: October 09, 2025

Showing 1-12 of 97

Last Updated: 09/26/2026